We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

59 hedge funds and large institutions have $251M invested in Y-mAbs Therapeutics in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 4

178% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 9

31% more funds holding

Funds holding: 45 → 59 (+14)

13% more capital invested

Capital invested by funds: $222M → $251M (+$28.6M)

7.29% more ownership

Funds ownership: 24.8% → 32.09% (+7.3%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
59
Holders Change
+14
Holders Change %
+31.11%
% of All Funds
1.28%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
25
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$18M
2
AG
Artal Group
Luxembourg
+$9.19M
3
CAM
Cormorant Asset Management
Massachusetts
+$6.53M
4
State Street
State Street
Massachusetts
+$5.51M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$4.71M

Top Sellers

Rank Fund Capital Flow
1
SCM
Scopia Capital Management
New York
-$24.1M
2
VIA
Vident Investment Advisory
Georgia
-$125K
3
TAM
Tiverton Asset Management
Delaware
-$78.1K
4
Barclays
Barclays
United Kingdom
-$72K
5
FCM
Flinton Capital Management
Pennsylvania
-$39K
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
1
Sofinnova Investments
California
$48.1M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$37.2M – – –
BlackRock
3
BlackRock
New York
$26.4M +$18M +784,672 +213%
CAM
4
Cormorant Asset Management
Massachusetts
$22.9M +$6.53M +284,518 +40%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$17.1M +$2.48M +108,054 +17%
AllianceBernstein
6
AllianceBernstein
Tennessee
$17M +$1.84M +80,149 +12%
Vanguard Group
7
Vanguard Group
Pennsylvania
$11.2M +$4.71M +205,021 +72%
Millennium Management
8
Millennium Management
New York
$9.21M +$2.69M +116,967 +41%
AG
9
Artal Group
Luxembourg
$9.15M +$9.19M +400,000 New
State Street
10
State Street
Massachusetts
$7.37M +$5.51M +239,895 +292%
Goldman Sachs
11
Goldman Sachs
New York
$5.17M +$25.3K +1,102 +0.5%
DCM
12
Driehaus Capital Management
Illinois
$4.57M +$4.59M +199,843 New
SFM
13
Sphera Funds Management
Israel
$4.34M +$4.36M +190,000 New
Geode Capital Management
14
Geode Capital Management
Massachusetts
$3.77M +$1.73M +75,509 +84%
Axa
15
Axa
France
$3.56M +$3.57M +155,642 New
Northern Trust
16
Northern Trust
Illinois
$2.61M +$747K +32,531 +40%
BBA
17
Baker Bros. Advisors
New York
$2.35M – – –
Stifel Financial
18
Stifel Financial
Missouri
$2.29M +$2.3M +100,000 New
N
19
Nuveen
North Carolina
$1.83M +$1.83M +79,898 New
AA
20
ALPS Advisors
Colorado
$1.64M +$1.64M +71,575 New
VIA
21
Vident Investment Advisory
Georgia
$1.52M -$125K -5,450 -8%
Charles Schwab
22
Charles Schwab
California
$1.51M +$695K +30,268 +85%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.32M +$864K +37,609 +186%
Renaissance Technologies
24
Renaissance Technologies
New York
$956K +$960K +41,800 New
JP Morgan Chase
25
JP Morgan Chase
New York
$739K +$71.5K +3,115 +10%
1
2 3

YMAB Hedge Fund Activity: Q2 2019 in Review

59 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q2 2019, worth a combined $251M — up 13% from $222M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new YMAB positions and 4 closed out — a net gain of 16 holders — while 25 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $18M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $24.1M sold.

  • 59 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q2 2019, up from 45 in Q1 2019.
  • Funds reported $251M of Y-mAbs Therapeutics stock for Q2 2019, up 13% quarter-over-quarter.
  • 20 funds opened new Y-mAbs Therapeutics positions in Q2 2019 and 4 closed out, a net change of +16 holders.
  • The largest Y-mAbs Therapeutics buyer in Q2 2019 was BlackRock, an estimated $18M added.
  • The largest Y-mAbs Therapeutics seller in Q2 2019 was Scopia Capital Management, an estimated $24.1M sold.

Based on aggregated 13F filings for Q2 2019.